View more in
Science

Dr Bijal Shah on the Toxicity in Phase 2 of ZUMA-3

ajmc.com
 2021-06-11

Cover picture for the articleThe phase 2 ZUMA-3 trial of brexucabtagene autoleucel showed that it is possible to intervene early to prevent some toxicity, said Bijal Shah, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center. The phase 2 ZUMA-3 trial of brexucabtagene autoleucel showed that it is possible to...

www.ajmc.com

Comments / 0

Comments / 0